JETRO Startup
Global Startup Acceleration Program (GSAP) AlumnisEditForce, Inc.
CIC '22 Bio/Healthcare
Healthcare Biotech
We strive to discover and develop gene therapy drugs based on our proprietary "PPR Platform Technology" , mainly in CNS, muscular, and rare diseases. We believe our RNA targeting approaches will achieve safer and more innovative therapies to reverse genomic DNA damage and restore normal gene function. We are committed to leveraging our innovative PPR Platform to discover and deliver breakthrough therapies to patients suffering from diseases worldwide.
Profile
- Year founded
- 15-May-15
- Name of the representative
- Yuki Tanabe / Director(Direct report to CEO), Business Development Dep.
- HQ location（City)
- Tokyo
- Total amount raised to date
- N/A (Unit：JPY thousand, USD mio)
- Stage
- Series C
- Major investors/VCs
- Partnership
- Major Clients
CEO/Team
*The contents of this page are subject to change without prior notice. Please contact us for the latest information.
